BioSpace News Archive

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a webinar on the importance of T-cell responses for COVID-19 vaccines on Monday, May 3, 2021 at 12:00 p.m. Eastern Time.

One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Monday, May 10, 2021,

Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced the appointment of William L. Greene, M.D. as the company’s chief executive officer, effective April 26, 2021.

- Preclinical evidence supports the development of LP-184 in non-small cell lung cancers (NSCLC) for patients ineligible for targeted therapy - LP-184 shows nanomolar potency in in vitro lung cancer models that are resistant to other cancer drugs

Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a mission-based, tech-enabled Medicare Advantage company, will release its 2021 first quarter financial results on Monday, May 17, 2021, after market close.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina.

– Company Establishes Agreement with Worldwide Clinical Trials to Conduct PK Study – – Anticipates initiating PK Study in June and Completion in Q3 2021 –

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business provides an update to the market on the progress of the US commercial availability of the Company’s COVID-19 Serious Disease Risk Test (‘COVID-19 Risk Test’) via US Based Infinity BiologiX LLC (‘IBX’),

Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the submission of an investigational new drug application (“IND”) to the United States Food and Drug Administration (“FDA”) for its immuno-oncology RNA therapy for the treatment of multiple cancers.